Transplant Center Research Team

The research we perform at the Ohio State Comprehensive Transplant Center covers basic, translational and clinical, with the goal of developing the next generation of surgical innovation. What we learn at the bench we apply to the bedside.


Current Research Studies:

Heart Transplant Research

AlloMap

Study Title: Outcomes AlloMap Registry: the Long-term Management and Outcomes of Heart Transplant Recipients with AlloMap Testing (OAR)
  • Weblink to Trial
  • Principal Investigator: Sitaramesh Emani, MD
  • Overview: The objective of this registry is to observe short and long term clinical outcomes in heart transplant recipients who receive regular AlloMap testing as part of allograft rejection surveillance.

Syncardia

Study Title: Syncardia 50cc TAH-t as a Bridge to Transplant
  • Weblink to Trial
  • Principal Investigator: Ahmet Kilic, MD
  • Overview: The primary objective of the study is to evaluate whether the 50cc TAH-t can safely support, and provide probable benefit to, transplant-eligible pediatric patients (aged 10 - 18 years) and can safely and effectively support transplant-eligible adult patients (aged 19 - 75 years) at imminent risk of death from biventricular failure without experiencing permanent disabling, stroke-related deficits.

Lung Transplant Research

Ex Vivo Lung Perfusion (EVLP)

Study Title: Novel Lung Trial: Normothermic Ex Vivo Lung Perfusion (EVLP) as an Assessment of Extended/Marginal Donor Lung for Transplant
  • Weblink to Trial
  • Principal Investigator: Bryan Whitson, MD, PhD
  • Overview: This multicenter study is evaluating the safety and efficacy of ex vivo lung perfusion (EVLP) using the XVIVO Perfusion System (XPS™). Human donor lungs that do not meet the standard clinical criteria for donor lung utilization but fit into the study inclusion criteria will be re-assessed by the transplant team. The lungs will then be physiologically assessed during ex vivo perfusion using Steen solution with the addition of methylprednisolone, heparin and antibiotics. EVLP can increase the number of lungs available for transplantation and assure good organ quality for transplantation.

Kidney Transplant Research

Long Term Outcomes of Living Donation or ALTOLD

Study Title: Assessing Long Term Outcomes of Living Donation or ALTOLD 
  • Principal Investigator: Todd Pesavento, MD 
  • Overview: The purpose of this study is to thoroughly evaluate the long-term risk, if any, of kidney donation. Specific aims are glomerular filtration rate, risk factors for cardiovascular disease, and proteinuria in healthy controls compared to subjects post-unilateral nephrectomy. This is a longitudinal study follow-up is occurring at eight sites and has been approved for nine years of follow-up.

Belatacept Switch with Delayed Graft Function

Study Title: Prospective, Randomized Trial of Belatacept Switch in Renal Transplant Recipients With Delayed Graft Function
  • Weblink to Trial 
  • Principal Investigator: Jon Von Visger, MD
  • Overview: This study is being conducted to determine if kidney transplant recipients with delayed graft function (DGF) who are switched to the immunosuppressive regimen of belatacept with mycophenolate and steroid will recover from delayed graft function (DGF) in less time (which could potentially lower the risk of rejection associated with delayed graft function) than kidney transplant recipients with delayed graft function (DGF) who remain on the current standard immunosuppressive regimen (standard of care).

Cinryze® for the Treatment of Acute Antibody-Mediated Rejection

Study TitleA Randomized Double-Blind Placebo-Controlled Study to Evaluate the Efficacy and Safety of Cinryze® (C1 Esterase Inhibitor [Human]) for the Treatment of Acute Antibody-Mediated Rejection in Kidney Transplant Patients
  • Weblink to Trial
  • Principal Investigator: Ronald Pelletier, MD
  • Overview: This is a multicenter, multinational study evaluating the efficacy of 20,000 total units of Cinryze given intravenously in 7 doses over 13 days as an adjunct to plasmapheresis and intravenous immunoglobulin (IVIg) for the treatment of acute antibody-mediated rejection in kidney transplant recipients as measured by the proportion of subjects with new or worsening transplant glomerulopahty (TG) within 6 months.

QPI-1002 for Prevention of Delayed Graft Function

Study Title: A Phase 3, Randomized, Double-blind, Placebo Controlled Study to Evaluate the Efficacy and Safety of QPI-1002 for Prevention of Delayed Graft Function in Recipients of a Donation After Brain Death Older Donor Kidney Transplant 
  • Weblink to Trial
  • Principal Investigator: Ashraf El-Hinnawi, MD 
  • Overview: This is a Phase 3 randomized, placebo-controlled, double-blind, multi-center trial stratified by donor age and by region to evaluate the reduction in incidence and severity of delayed graft function with kidney allografts from DBD donors who were at least 45 years of age.

Sirolimus and Everolimus in Combination with Low Dose Cyclosporine

Study Title: Differentiating Sirolimus and Everolimus in Combination with Low Dose Cyclosporine in De Novo Kidney Transplant Patients—The Effects on Vascular Endothelial and Kidney Function
  • Principal Investigator: Ronald Pelletier, MD
  • Overview: This is an optional sub-study for patients enrolled in the Zortress vs. Rapamune research study with Dr. Pelletier. For this sub-study we are working with a researcher at the University of Colorado, Uwe Christians, MD, to extend the Zortress vs Rapamune study into the laboratory. By extending the study into the laboratory we will be able to test plasma from transplant patients for specific molecular markers related to kidney and vascular function. This testing will allow us to see how different medications affect these molecular markers and thus how different medications affect kidney and vascular function.

Comparing Everolimus and Sirolimus in Renal Transplant Recipients

Study Title: A Prospective, Randomized, Single Center Pilot Study Comparing Patient and Graft Survival, Adverse Events and Tolerability of Zortress® (Everolimus) Versus Rapamune® (Sirolimus) in Combination With Low Dose Neoral® (Cyclosporine) Dosed by C2 Monitoring, in Deceased and Living Donor Renal Transplant Recipients Under a Thymoglobulin® (Antithymocyte Globulin) and Rapid Steroid Induction Protocol.

  • Weblink to Trial
  • Principal Investigator: Ronald Pelletier, MD
  • Overview: The primary objective of this pilot study will be to determine equivalency of Zortress® as compared to Rapamune® when used in our de novo immunosuppression regimen following renal transplantation. The primary endpoint will be a composite endpoint of graft survival (non-death censored) and biopsy proven acute rejection at 1 year. The primary outcome of immunosuppressive protection would be studied in our Thymoglobulin and rapid steroid discontinuation protocol, with "half-dose" Neoral as described above.

T Cell Immune Profiles and Alloantibody Levels and Isotypes from Peripheral Blood

Study Title: Investigation of Cytokine Gene Polymorphisms, T Cell Immune Profiles and Alloantibody Levels and Isotypes from Peripheral Blood in Primary Kidney Transplant Patients
  • Principal Investigator: Ginny Bumgardner, MD
  • Overview: The purpose of this study is to investigate the effect of mTOR inhibition dosing and levels in the presence or absence of calcineurin inhibition on the quantity and isotype of de novo post-transplant alloantibody and to correlate these findings with concurrent CD8:CD4 T cell ratios, CD4+ T cell IL-4:INFg cytokine ratios, cytokine/cytokine receptor gene polymorphisms, race, and gender in primary human kidney transplant recipients. This study has a one year follow-up.

Islet Transplant Research

Islet Allotransplantation in Type 1 Diabetes

Study Title: Islet Allotransplantation in Type 1 Diabetes
  • Weblink to Trial
  • Principal Investigator: Amer Rajab, MD, PhD
  • Overview: This is a single center, prospective, phase 1 study investigating the use of islet transplantation for the treatment of type 1 diabetes in subjects receiving islets alone or islets after kidney transplant.  The aims of this study are to determine the safety of islet transplantation, to determine whether islet transplantation will reduce the frequency of severe hypoglycemia events, to determine whether a steroid-free immunosuppressive protocol will prevent rejection in islet transplants, and to achieve insulin independence after islet transplant.  A total of 20 subjects will be transplanted with a 12-month follow-up after the last transplantation.

Research Grants

Active Grants

Active and Pending Grants 
  • Ginny Bumgardner MD, PhD - Advanced research training in immunology for surgery trainees (ARTIST), National Institutes of Health (NIH, NIAID), 8/15/2014-7/31/2019, $728,445
  • Jason Zimmerer PhD, Ginny Bumgardner MD, PhD - DOS Lockwood Early Career Development Award, Investigation of Cytokine Gene Polymorphisms, T Cell Profiles and Alloantibody Levels and Isotypes from Peripheral Blood in Primary Kidney Transplant Patients, 11/5/2014-11/5/17, $25,000  
  • Ginny Bumgardner MD, PhD - Type I NKT cell mediated enhance of CD8+ Cytolytic T cells, 1/1/2018-12/31/2023, pending submission 6/5/17 
  • Ginny Bumgardner MD, PhD - Novel mechanisms regulating post-transplant alloantibody productions, 10/1/2017-9/30/2022, pending competitive renewal 7/5/17
Recently Completed Grants 
  • Ginny Bumgardner MD, PhD - Novel mechanisms regulating post-transplant alloantibody productions, NIH RO1, 9/1/2011-8/31/2016, $1,527,967 
  • Ginny Bumgardner MD, PhD - Demographic and Clinical Factors and Transplant Outcomes Associated with Hospital Readmissions within the First Year after Kidney Transplantation in Adult Recipients, OSU Comprehensive Transplant Center, 05/30/2015-12/30/2016  

Our Researchers

From Our Experts

Research Opportunities in the Division of Transplantation Surgery at Ohio State

Ex Vivo Lung Perfusion Clinical Trial

Read more

Effects of Space Microgravity on the Heart

Read more

Islet Transplantation Clinical Trial May Cure Type 1 Diabetes

Read more

Share this Page